Consumer

The short answer is: “It depends” (on strategy, focus and structure). A quick rule of thumb is 3 people per $100m in the fund.

The Arm-backed accelerator picked six companies for its largest cohort yet, focusing on hardware, manufacturing and knowledge.

Qualcomm bought portfolio company Cellwize for $350m while Northrop Grumman took part in a $135m round for radar technology producer Echodyne.

SR One co-led antibody therapy developer Ancora Biotech's $60m series A round while Al-Dhow Engineering helped coffee chain Flash Coffee secure $32.8m.

American Family helped digital auto insurance portal Branch secure $147m while Anthem, Optum and CVS Health all contributed to a $140m round for home care platform developer CareBridge.

GV participated in tech apprenticeship platform Multiverse’s $220m series D round while Amgen, UCB, UPMC and Takeda helped genetics disease drug developer Code Biotherapeutics raise $75m.

GCV has spoken to several corporate and VC investors about the recent hit to Australia's startup scene following a post-lockdown deal surge.

It pays to invest in these companies. Research shows they are less likely to fail and will attract two to three times more investment.

The number of corporate-backed deals dropped by 13% year-on-year in May, the first clear sign that the market pullback is having an impact.

SoftBank Latin America Fund is among the investors in payment technology provider Kushki’s $186m series B round while Maruho co-led inflammatory disease drug developer Upstream's $200m series A.

Envision Group’s Envision Digital subsidiary raised $210m in series A funding while Sarnoff Corporation’s Intuity Medical spinoff will shut down at the start of July.